Ampio Pharmaceuticals Inc Stock News
$0.242
+0.0216 (+9.82%)
At Close: May 17, 2024
Ampio Pharmaceuticals shares are trading higher after Roth Capital Partners initiated coverage on the stock with a Buy rating.
09:15pm, Wednesday, 18'th Dec 2019Ampio Provides Update on AP-013 Phase III Clinical Trial and Annual Meeting Conference Call Number
01:30pm, Wednesday, 04'th Dec 2019
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment (SPA) Phase III clinical trial titled "Evaluating the Efficacy
Ampio Provides Update on AP-…–' Phase III Clinical Trial and Annual Meeting Conference ...
12:00am, Wednesday, 04'th Dec 2019Private Capital Management Llc Buys Ampio Pharmaceuticals Inc, AT&T Inc, Comcast Corp, ...
12:00am, Wednesday, 16'th Oct 2019Ampio Provides Update on Continued Progress of AP-013 Phase III Clinical Trial and Manufacturing Facility
12:30pm, Thursday, 10'th Oct 2019
ENGLEWOOD, Colo., Oct. 10, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment (SPA) Phase III
Ampio Pharma Offers Update On Continued Progress Of AP-013 Phase 3 Trial, Manufacturing Facility
12:00am, Thursday, 10'th Oct 2019Ampio Retains Legal Counsel for Transaction Advisory Committee
12:30pm, Wednesday, 18'th Sep 2019
ENGLEWOOD, Colo., Sept. 18, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment (SPA) phase t
Ampio Pharmaceuticals Updates Progress of SPA Clinical Trial
12:30pm, Tuesday, 17'th Sep 2019
ENGLEWOOD, Colo. , Sept. 17, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) today announced the progress to date in the Company's special protocol assessment (SPA) phase t
Ampio Pharmaceuticals Retains Financial Advisor and Appoints Transaction Advisory Committee
12:30pm, Thursday, 22'nd Aug 2019
ENGLEWOOD, Colo., Aug. 22, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a development stage biopharmaceutical company, executing a special protocol assessment (SPA) phase th
